Fluicell AB (DE:5J90)
FRANKFURT:5J90
5J90 Stock Chart & Stats
€1.29
--
Market closed
€1.29
--
Day’s Range― - ―
52-Week Range€0.67 - €2.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)94.00
Market Cap
€1.72M
Enterprise Value€17.11M
Total Cash (Recent Filing)€2.26M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta27.18
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,373,703
10 Day Avg. Volume182
30 Day Avg. Volume94
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€6.35M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtA zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to time funding and investment. Over 2–6 months this lowers bankruptcy risk and supports strategic options (R&D, partnerships) without immediate leverage constraints.
Strong Recent Revenue ReboundA ~124% TTM revenue rebound signals recovering commercial traction for instruments and consumables. If sustained, this trend supports scale benefits, stronger unit economics for consumables and improved revenue visibility, helping narrow operating losses over multiple quarters.
Focused Niche Product PlatformA specialized microfluidics platform targets a durable, growing single-cell research market. The focused product set and platform nature support recurring consumable sales and deepen technical moats with specialized users, enabling steadier long-term demand and partnerships.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow implies reliance on external funding and dilution risk. Over the next several quarters, continued cash burn can constrain R&D and go-to-market investments and force financing at unfavorable terms, limiting strategic optionality.
Ongoing Net Losses And Weak MarginsMaterial operating losses and negative net margins indicate the business is not yet self-sustaining. Without sustained margin improvement and scalable gross margins, profitability remains distant, which impairs internal capital generation and increases dependency on external funding.
Eroding Equity BaseDeclining shareholders' equity reflects accumulated losses that reduce the balance-sheet buffer. A thinner capital base weakens resilience to shocks, raises future fundraising needs, and can increase cost of capital or dilution risk if additional equity financing is required within the medium term.
5J90 FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was €0.67 and its highest was €2.04 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is €1.72M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is May 08, 2026 which is in 28 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on Feb 20, 2026. The company reported €0.007 earnings per share for the quarter, beating the consensus estimate of N/A by €0.007.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of €0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 28.409%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in DE:5J90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.